Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer

• Published in: Anti-cancer drugs Vol. 31; no. 7; p. 702
• Main Authors: Zhang, Na, Sun, Pan, Jin, Haizhen, Yang, Yuqin, Zhao, Qingya, Zhou, Lin, Guo, Lili, Yang, Xiaohua, Lu, Liming
• Format: Journal Article
• Language: English
• Published: England 01.08.2020
• Subjects: Aminopyridines - administration & dosage; Aminopyridines - pharmacology; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis - drug effects; Benzamides - administration & dosage; Benzamides - pharmacology; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - enzymology; Carcinoma, Non-Small-Cell Lung - pathology; Cell Cycle - drug effects; Histone Deacetylase 6 - biosynthesis; Histone Deacetylase 6 - metabolism; Histone Deacetylase Inhibitors - administration & dosage; Histone Deacetylase Inhibitors - pharmacology; Histone Deacetylases - biosynthesis; Histone Deacetylases - metabolism; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - enzymology; Lung Neoplasms - pathology; Paclitaxel - administration & dosage; Paclitaxel - pharmacology; Proto-Oncogene Proteins c-myc - antagonists & inhibitors; Proto-Oncogene Proteins c-myc - biosynthesis; Tumor Cells, Cultured

The role of histone deacetylases (HDACs) in lung cancer has been extensively studied. Inhibition of HDAC activities have been used as a new cancer treatment strategy. To date, many HDAC inhibitors have been shown to induce apoptosis and inhibit tumorigenesis. Chidamide (CS055) is a new member of HDA...